-
公开(公告)号：US07855275B2
公开(公告)日：2010-12-21
申请号：US12399241
申请日：2009-03-06
IPC分类号： C07K16/00
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合，形成具有式I：Ab- （LD）p I，其中p为1至4.披露了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US20110137017A1
公开(公告)日：2011-06-09
申请号：US12971197
申请日：2010-12-17
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合，形成具有式I：Ab- （LD）p I，其中p为1至4.披露了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US20090175865A1
公开(公告)日：2009-07-09
申请号：US12399241
申请日：2009-03-06
IPC分类号： A61K39/395 , C07K16/46 , A61P35/00
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗体 - 药物共轭物： in-line-formula description =“In-line Formulas”end =“lead”？> Ab-（LD）p I <？in-line-formula description =“In-line Formulas”end =“tail”？> where p是1至4.公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US07521541B2
公开(公告)日：2009-04-21
申请号：US11233258
申请日：2005-09-22
IPC分类号： C07K16/00
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗体 - 药物共轭物： in-line-formula description =“In-line Formulas”end =“lead”？> Ab-（LD）p I <？in-line-formula description =“In-line Formulas”end =“tail”？> where p是1至4.公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US08309300B2
公开(公告)日：2012-11-13
申请号：US12427649
申请日：2009-04-21
IPC分类号： C12Q1/70
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合，形成具有式I：Ab- （LD）p I，其中p为1至4.披露了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
6.发明申请公开(公告)号：US20090117100A1
公开(公告)日：2009-05-07
申请号：US12288181
申请日：2008-10-16
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00 , C12P21/00 , G01N33/574
CPC分类号： C07K16/28 , A61K38/05 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6889 , A61K2039/505 , C07K16/30 , C07K16/3069 , C07K2317/14 , C07K2317/24 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/73 , C07K2317/77 , G01N33/574 , G01N33/57492
摘要： Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的反应性半胱氨酸氨基酸替代亲本抗TENB2抗体的一个或多个氨基酸来工程化半胱氨酸改造的抗TENB2抗体。 提供了设计，制备，筛选和选择半胱氨酸改造的抗TENB2抗体的方法。 通过接头（L）将半胱氨酸改造的抗TENB2抗体（Ab）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗TENB2抗体 - 药物共轭物：<β在线配方描述= “直线公式”end =“lead”？> Ab-（LD）p I <？in-line-formula description =“In-line Formulas”end =“tail”？>其中p为1到4.诊断 并公开了半胱氨酸改造的抗体药物化合物和组合物的治疗用途。
-
公开(公告)号：US20080305106A1
公开(公告)日：2008-12-11
申请号：US11568901
申请日：2005-04-12
申请人： Jane Brennan , Frederic J. de Sauvage , Ellen Filvaroff , Iqbal Grewal , Bryan Irving , Jagath Reddy Junutula , Daniel Kirchhofer , Franklin Peale , Heide Phillips , Tracy Tang , Dineli Wickramasinghe , Weilan Ye
发明人： Jane Brennan , Frederic J. de Sauvage , Ellen Filvaroff , Iqbal Grewal , Bryan Irving , Jagath Reddy Junutula , Daniel Kirchhofer , Franklin Peale , Heide Phillips , Tracy Tang , Dineli Wickramasinghe , Weilan Ye
IPC分类号： A61K39/395 , C12Q1/68 , C12N5/06 , A61K38/00 , A61P19/00 , A61P27/00 , A01K67/027 , C07K16/18
CPC分类号： A01K67/0275 , A01K67/0278 , A01K2217/05 , A01K2217/072 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C07K14/4703 , C07K14/705 , C12N15/8509
摘要： The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO256, PRO34421, PRO334, PRO770, PRO983, PRO1009, PRO1107, PRO1158, PRO1250, PRO1317, PRO4334, PRO4395, PRO49192, PRO9799, PRO21175, PRO19837, PRO21331, PRO23949, PRO697 or PRO1480 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
摘要翻译： 本发明涉及转基因动物，以及与基因功能表征相关的组合物和方法。 具体地，本发明提供转基因小鼠，其包括PRO256，PRO34421，PRO334，PRO770，PRO983，PRO1009，PRO1107，PRO1158，PRO1250，PRO1317，PRO4334，PRO4395，PRO49192，PRO9799，PRO21175，PRO19837，PRO21331，PRO23949，PRO697或PRO1480中的中断 基因。 这样的体内研究和表征可以提供有用的识别和发现治疗和/或治疗用于预防，改善或矫正与基因中断相关的疾病或功能障碍如神经障碍; 心血管，内皮或血管生成障碍; 眼睛异常; 免疫学障碍; 肿瘤疾病; 骨代谢异常或障碍; 脂代谢紊乱 或发育异常。
-
公开(公告)号：US08691531B2
公开(公告)日：2014-04-08
申请号：US13305493
申请日：2011-11-28
申请人： Yvonne Chen , Mark Dennis , David Dornan , Kristi Elkins , Jagath Reddy Junutula , Andrew Polson , Bing Zheng
发明人： Yvonne Chen , Mark Dennis , David Dornan , Kristi Elkins , Jagath Reddy Junutula , Andrew Polson , Bing Zheng
CPC分类号： C07K16/2896 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2803 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , Y02A50/412
摘要： The present invention is directed to compositions of matter comprising nucleic acids encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 207 or 208, encoding an anti-CD79b antibody comprising the heavy chain variable domain sequence of SEQ ID NO: 207 and the light chain variable domain sequence of SEQ ID NO: 208, or encoding an anti-CD79b antibody having : (i) a variable light chain comprising a HVR-L1 having the sequence of SEQ ID NO: 194, a HVR-L2 having the sequence of SEQ ID NO: 195, and a HVR-L3 having the sequence of SEQ ID NO: 196 and (ii) a variable light chain comprising a HVR-H1 having the sequence of SEQ ID NO: 202, a HVR-H2 having the sequence of SEQ ID NO: 203, and a HVR-H3 having the sequence of SEQ ID NO: 204, and vectors and host cells thereof.
摘要翻译： 本发明涉及包含编码包含SEQ ID NO：207或208的氨基酸序列的多肽的核酸的物质组合物，编码包含SEQ ID NO：207的重链可变结构域序列的抗CD79b抗体和 SEQ ID NO：208的轻链可变结构域序列，或编码抗CD79b抗体，其具有：（i）包含具有SEQ ID NO：194的序列的HVR-L1的可变轻链，具有序列的HVR-L2 具有SEQ ID NO：196的序列的HVR-L3和（ii）包含具有SEQ ID NO：202的序列的HVR-H1的可变轻链，HVR-H2具有SEQ ID NO： SEQ ID NO：203的序列和具有SEQ ID NO：204的序列的HVR-H3，以及其载体和宿主细胞。
-
9.发明申请公开(公告)号：US20090068202A1
公开(公告)日：2009-03-12
申请号：US12173667
申请日：2008-07-15
申请人： Yvonne Chen , Mark Dennis , Kristi Elkins , Jagath Reddy Junutula , Andrew Polson , Bing Zheng
发明人： Yvonne Chen , Mark Dennis , Kristi Elkins , Jagath Reddy Junutula , Andrew Polson , Bing Zheng
IPC分类号： A61K39/395 , C07K16/00 , C07K14/00 , C07H21/00 , G01N33/53 , A61P35/00 , C07K1/00 , C12N15/63 , C12N5/00 , C12P21/00
CPC分类号： C07K16/2803 , A61K39/39541 , A61K39/39558 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , Y02A50/412
摘要： The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要翻译： 本发明涉及可用于治疗哺乳动物造血肿瘤的物质组合物，以及使用这些物质组合物的方法。
-
10.发明授权公开(公告)号：US08937161B2
公开(公告)日：2015-01-20
申请号：US12288181
申请日：2008-10-16
CPC分类号： C07K16/28 , A61K38/05 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6889 , A61K2039/505 , C07K16/30 , C07K16/3069 , C07K2317/14 , C07K2317/24 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/73 , C07K2317/77 , G01N33/574 , G01N33/57492
摘要： Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的反应性半胱氨酸氨基酸替代亲本抗TENB2抗体的一个或多个氨基酸来工程化半胱氨酸改造的抗TENB2抗体。 提供了设计，制备，筛选和选择半胱氨酸改造的抗TENB2抗体的方法。 半胱氨酸改造的抗TENB2抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I：Ab-（LD）p I的半胱氨酸改造的抗TENB2抗体 - 药物共轭物，其中p 公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.048 秒)